[1]张良文,张严晖,王晓瑄,等.国产二价HPV疫苗接种的成本效果分析 ——基于Markov模型[J].卫生经济研究,2025,42(11):32-37.
　ZHANG Liangwen,ZHANG Yanhui,WANG Xiaoxuan,et al.Cost-Effectiveness Analysis of Domestically Produced Bivalent HPV Vaccination in China ——Based on a Markov Model[J].Journal Press of Health Economics Research,2025,42(11):32-37.
点击复制

国产二价HPV疫苗接种的成本效果分析
——基于Markov模型

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年11期
页码:
32-37
栏目:
成本与费用
出版日期:
2025-11-04

文章信息/Info

Title:
Cost-Effectiveness Analysis of Domestically Produced Bivalent HPV Vaccination in China
——Based on a Markov Model
作者:
张良文1; 2; 3; 张严晖1; 2; 3; 王晓瑄1; 2; 3; 魏翘楚1; 2; 3; 唐潮彬1; 2; 3; 方 亚1; 2; 3
1.传染病疫苗研发全国重点实验室，福建 厦门 361102
2.国家医学攻关产教融合创新平台（疫苗研发），福建 厦门 361102
3.厦门大学公共卫生学院卫生技术评估福建省高校重点实验室，福建 厦门 361102
Author(s):
ZHANG Liangwen;  ZHANG Yanhui;  WANG Xiaoxuan;  WEI Qiaochu;  TANG Chaobin;  FANG Ya
National Key Laboratory of Infectious Disease Vaccine R&D, National Innovation Platform for Industry-Education Integration in Medical Research(Vaccine R&D), Fujian Key Laboratory of Health Technology Assessment, School of Public Health, Xiamen Universi
关键词:
宫颈癌; 人乳头瘤病毒疫苗; 成本效果分析
Keywords:
cervical cancer;  human papillomavirus vaccine;  cost-effectiveness analysis
分类号:
R19
文献标志码:
A
摘要:
目的：评估国产二价HPV疫苗接种联合宫颈癌筛查的经济性，探索适合中国国情的宫颈癌干预策略。方法：构建Markov模型，评估由筛查方法、筛查频率、疫苗接种等要素组成的41种宫颈癌干预策略的经济性。结果：当支付意愿为我国人均GDP时，接种国产二价疫苗并结合三年一次VIA筛查是最具成本效果的宫颈癌干预策略；敏感性分析显示，模型结果稳健，疫苗和筛查方法价格及覆盖率等参数可能是影响成本效果的主要因素。结论：建议在免疫规划中逐步推广国产二价HPV疫苗常规接种与三年周期VIA筛查相结合的宫颈癌协同干预策略，通过优化资源配置降低成本，提升宫颈癌干预的有效性和经济性。
Abstract:
Objective To evaluate the economics of the first domestically produced bivalent HPV vaccination combined with cervical cancer screening in China, and to explore cervical cancer prevention strategies suitable for China. Methods A Markov model was constructed to evaluate the economics of 41 immunization strategies consisting of different cervical cancer screening methods, screening frequency, and whether or not to vaccinate. Results When willingness to pay was China's gross domestic product per capita, vaccination combined with triennial visual inspection of acetic acid(VIA) screening was the most cost-effective strategy. Sensitivity analyses showed robust model results, and parameters such as vaccine and screening method prices and vaccine and screening coverage may be relevant factors influencing cost-effectiveness results. Conclusion It is recommended that the synergistic intervention strategy of combining routine domestic bivalent HPV vaccination with three-year cycle VIA screening should be gradually promoted in immunization planning, and the implementation cost should be reduced by optimizing the allocation of resources, so as to enhance the effectiveness and economy of cervical cancer interventions.

参考文献/References:

[1] World Health Organization.Cervical cancer[EB/OL].(2022-02-22)[2022-03-03].https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.
[2] Sung H,Ferlay J,Siegel R L,et al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(03): 209-249.
[3] Arbyn M,Weiderpass E,Bruni L,et al.Estimates of incidence and mortality of cervical cancer in 2018:a worldwide analysis[J].Lancet Glob Health,2020,8(02):e191-e203.
[4] Cao W,Chen HD,Yu YW,et al.Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J].Chin Med J(Engl),2021,134(07):783-791.
[5] 李明珠，赵方辉，尹如铁,等.预防性人乳头瘤病毒疫苗中国临床应用指南（2025版）[J].中国妇产科临床杂志，2025，26（02）：176-187.
[6] 国家药品监督管理局.首个国产重组人乳头瘤病毒疫苗获批上市[EB/OL]. （2019-12-31）[2022-03-03].https://www.nmpa.gov.cn/yao wen/ypjgyw/20191231160701608.html.
[7] World Health Organization,Human papillomavirus vaccines:WHO position paper[EB/OL].[2022-03-03].https://www.who.int/publications/i/item/who-wer9750-645-672.
[8] 陶思源，彭介入，王英，等.子宫颈癌及癌前病变患者直接经济负担及其影响因素研究[J].中华预防医学杂志，2018，52（12）：1281-1286.
[9] 贺宇彤，刘言玉，高玮,等.2018—2019年河北省城市人群乳腺癌筛查结果的分析[J].中华预防医学杂志，2021，55（04）：535-538.
[10] Zou Z,Fairley C K,Ong J J,et al.Domestic HPV vaccine price and economic returns for cervical cancer prevention in China:a cost-effectiveness analysis[J].Lancet Glob Health,2020,8(10): e1335-e1344.
[11] 宋晓彬，茅范贞，周鼒，等.发展中国家人乳头瘤病毒疫苗卫生经济学评价研究的系统综述[J].中华预防医学杂志，2016，50（01）：85-90.
[12] DeGroff A,Cheung K,Dawkins-Lyn N,et al.Identifying promising practices for evaluation:the National Breast and Cervical Cancer Early Detection Program[J].Cancer Causes Control,2015,26(05): 767-774.
[13] Qiao Y L,Wu T,Li R C,et al.Efficacy,safety,and immunogenicity of an escherichia coli-produced bivalent Human Papillomavirus Vaccine: an interim analysis of a randomized clinical trial[J].J Natl Cancer Inst,2020,112(02):145-153.
[14] World Health Organization,WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.[2022-03-03].https://www.who.int/news/item/06-07-2021-q-and-a-screening-and-treatment-cervical-pre-cancer-lesions-for-cervical-cancer-prevention#:~:text=This%20WHO%20and%20HRP%20guideline%20in%20its%20second,on%20the%20screening%20and%20treatment%20of%20cervical%20cancer.
[15] 张梅，包鹤龄，王丽敏，等.2015年中国宫颈癌筛查现况及相关因素分析[J].中华医学杂志，2021，101（24）：1869-1874.
[16] 张晓晗,胡尚英,赵方辉,等.中国宫颈癌筛查服务政策量化分析[J].中国公共卫生,2024,40(05):521-527.
[17] You T,Zhao X,Hu S,et al.Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: a modelling study[J].E Clinical Medicine,2023,56:101789.
[18] Zhou L,Gu B,Wang J,et al.Human papillomavirus vaccination at the national and provincial levels in China:a cost-effectiveness analysis using the PRIME model [J].BMC Public Health,2022,22(01) :777.
[19] Joura E A,Giuliano A R,Iversen O E,et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women [J].N Engl J Med,2015,372(08):711-723.

相似文献/References:

[1]向 芳,李 胜,郝 莲,等.2003—2017年中国女性宫颈癌死亡趋势分析——基于年龄—时期—队列模型[J].卫生经济研究,2020,(05):23.
　XIANG Fang,LI Sheng,HAO Lian,et al.Analysis on Chinese Women's Cervical Cancer Death Trends from 2003 to 2017——Based on Age-Period-Cohort Model[J].Journal Press of Health Economics Research,2020,(11):23.
[2]文雪莲,热米拉·热扎克,唐月红.2010—2020年新疆宫颈癌经济负担及筛查覆盖率的影响研究[J].卫生经济研究,2024,41(05):32.
　WEN Xuelian,Remila REZHAKE,TANG Yuehong.Study on the Economic Burden of Cervical Cancer and the Impact of Screening Coverage in Xinjiang from 2010 to 2020[J].Journal Press of Health Economics Research,2024,41(11):32.

更新日期/Last Update: 2025-11-04